Teva Pharmaceutical Industries Ltd.
) recently announced that its 91-day oral contraceptive,
Quartette, gained FDA approval for the prevention of
Quartette, a next-generation extended regimen oral
contraceptive, has been shown to reduce breakthrough bleeding
(BTB) between scheduled periods. BTB, which is usually
experienced during the first few months of using a birth control
pill, is a major reason for the discontinuation of extended
regimens by several women.
Results on Quartette showed a decline in BTB and unscheduled
spotting over successive 91 day cycles. Meanwhile, Teva said that
Quartette has been shown to be 97% effective in preventing
Quartette's launch should help boost sales of Teva's Women's
Health segment which came in at $448 million in 2012. Teva's
Women's Health segment focuses on several therapeutic areas
including oral contraceptives, hormone therapy treatments for
menopause/perimenopause, and therapies for use in infertility and
Key products in Teva's Women's Health portfolio include Plan B
One-Step OTC/Rx (an emergency oral contraceptive), ParaGard T380
A (a non-hormonal intrauterine copper contraceptive), Zoely (a
28-day regimen combination contraceptive oral pill) and Enjuvia
(an oral treatment for moderate to severe vasomotor symptoms
associated with menopause).
Other candidates in Teva's Women's Health pipeline include
Milprosa (luteal support for in vitro fertilization - a response
to the FDA's previously issued complete response letter is
expected in 2013), DR-3001 (overactive bladder), XM17 (treatment
of female infertility - application submitted in Europe) and
LeCette (28-day oral contraceptive - currently in phase III with
a new drug application filing expected in 2013).
Teva currently carries a Zacks Rank #3 (Hold). The company is
going through a transition period. Headwinds include EU pricing
pressure, new competition for branded products (especially
multiple sclerosis drug, Copaxone) and fewer generic product
launches compared to 2012. Competition in the multiple sclerosis
market will increase given the recent FDA approval of
) oral multiple sclerosis product, Tecfidera.
Currently, companies like
) look more attractive. Both are Zacks Rank #2 (Buy) stocks.
Meanwhile, Biogen is a Zacks Rank #1 (Strong Buy) stock.
AKORN INC (AKRX): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.